Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Saturday, October 24, 2015

Biogen reports negative data on natalizumab in Phase III multiple sclerosis trial

US biotech company Biogen (Nasdaq: BIIB) has reported negative data from the Phase III trial of natalizumab, its blockbuster drug Tysabri, in secondary progressive multiple sclerosis.
The ASCEND trial evaluated the safety and efficacy of natalizumab to slow the accumulation of disability progression unrelated to relapse in secondary progressive multiple sclerosis patients, where the majority of study participants had EDSS scores of 6.0 to 6.5 which indicates a walking aid is required. They were non-relapsing for two years prior to enrolling in the study. The composite primary endpoint of the study evaluated the percentage of patients whose disability had progressed on one of more of three disability measurements comprising the composite endpoint. Natalizumab showed a significant effect on upper limb function unrelated to relapses.

MS Views and News helps to provide information for all affected by MS
Keep up to date with the news and information we provide 
by signing up by clicking here

No comments: